Bladder cancer screening: The new selection and prediction model DOI Creative Commons
Vladan Radosavljević, Nataša Milić

Open Medicine, Journal Year: 2023, Volume and Issue: 18(1)

Published: Jan. 1, 2023

Abstract The objective of this study was to offer new approach for selection persons with asymptomatic bladder cancer (BC) and highly risky the BC occurrence. Also, it is a part screening protocol (study ongoing). Study populations were 100 newly diagnosed (diagnosis maximum 1-year old) males matched (by sex age ±5 years) controls (not oncology patients from same hospital). A hospital based, case–control done. Statistical analysis comprised four steps: t -test, univariate logistic regression, multivariate scoring. fifth step two changes, deleting one variable addition another variable. Six variables statistically significant: Caucasian men over 45 years age, tobacco smoking 40 pack-years, occupational and/or environmental exposure proved carcinogens 20 years, macrohematuria, difficulty urinating, in relatives up fourth degree kinships, they used an easy fast individuals high risk occurrence (optimal at population level). final results showed significant probability ( p < 0.001), area under ROC curve 0.913, negative predictive values 89.7% (95% CI 10.3–100%), specificity 78%. Positive value 80.5% 19.5–100%) sensitivity 91%. It possible recruit (primary prevention) by using model, as well (primordial prevention). This first second ongoing (urine analysis).

Language: Английский

Diagnostic Performance of Biomarkers for Bladder Cancer Detection Suitable for Community and Primary Care Settings: A Systematic Review and Meta-Analysis DOI Open Access
Evangelia Papavasiliou, Valerie A. Sills, Natália Calanzani

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(3), P. 709 - 709

Published: Jan. 24, 2023

Evidence on the use of biomarkers to detect bladder cancer in general population is scarce. This study aimed systematically review evidence diagnostic performance which might be suitable for community and primary care settings [PROSPERO Registration: CRD42021258754]. Database searches MEDLINE EMBASE from January 2000 May 2022 resulted 4914 unique citations, 44 met inclusion criteria. Included studies reported 112 combinations. Heterogeneity designs, populations outcomes allowed meta-analysis three identified at least five (NMP-22, UroVysion, uCyt+). These showed similar discriminative ability (adjusted AUC estimates ranging 0.650 0.707), although NMP-22 UroVysion there was significant unexplained heterogeneity between included studies. Narrative synthesis revealed potential these based their clinical utility, including effects clinicians, patients, healthcare system. Finally, we some promising novel biomarker combinations (N < 3 each biomarker/combination) with negative predictive values ≥90%. have as a triage tool reducing unnecessary specialist referrals. Despite emerging evidence, further validation are required different stages within pathway.

Language: Английский

Citations

3
Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action DOI Creative Commons
Veronica Nanton, Richard T. Bryan,

Anne M Pope

et al.

BMJ Oncology, Journal Year: 2023, Volume and Issue: 2(1), P. e000092 - e000092

Published: Nov. 1, 2023

Recruitment and retention in cancer trials are long-standing issues, exacerbated by the COVID-19 pandemic. The UK National Institute of Health Research leading clinicians have emphasised urgency to achieve surpass prepandemic levels participation. Data from a recent trial demonstrated impact highlighted factors that limited recruitment. In response this worldwide problem, studies identified strategies for remediation at funding, research environment, study design team-related aspects, yet evidence progress is lacking. Equality, diversity inclusivity become central health social policy during 2000s. need greater has particular concern researchers funders USA, recognition potential bias results. trials, lack standardised recording ethnicity data renders interpretation difficult caution required comparisons with USA. Recently, focus shifted away deprivation low socioeconomic status on Barriers created these their frequent intersection should not be overlooked. adopted an advisory approach broadening recruitment, publishing documents, guidance toolkits. contrast, action inclusion increasingly mandated. Within paradigm, community strongly encouraged adopt coordinated towards digital collection embed evaluate innovative, cocreated, locally relevant strategies.

Language: Английский

Citations

3
Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy DOI Creative Commons
Prithvi Murthy, Billie Gould, Facundo Davaro

et al.

Société Internationale d’Urologie Journal, Journal Year: 2023, Volume and Issue: 4(4), P. 247 - 256

Published: July 14, 2023

ObjectiveTo assess the ability of cell-free urinary and plasma tumor DNA (cfDNA) to predict pathologic stage at radical cystectomy for patients with clinical muscle-invasive bladder cancer. MethodsA total 25 cancer were enrolled before undergoing cystectomy. Blood urine collected surgery. The 600-gene PredicineATLAS panel was used sequence blood buffy-coat germline DNA, cfDNA, cfDNA samples. Low-pass whole genome sequencing performed on plasma- urine-derived cfDNA. CfDNA fraction (TF), genome-wide copy number burden (CNB), estimated mutational (TMB) measured in both samples their correlation T-stage examined. ResultsThree had insufficient In 22 24 samples, least one nonsynonymous somatic variant detected. Across cohort, 44% variants concordant paired variants. mean did not differ between noninvasive (< pT1/pN0) invasive disease (≥ pT1 or N+) (8 vs. 9.5 variants; P = 0.85) (33.7 30 0.45). A strong observed TF CNB score within (rv 0.92). Plasma (r 0.38), 0.21), 0.16) exhibited positive correlations pT stage. Patients carcinoma situ (CIS) higher scores ( 0.07 0.05, respectively). correlate presence CIS.ConclusionsCombining urine-based analysis may help identify residual radical, although we unable based these metrics.The CIS contribute greater levels. Considering improve metrics sequencing–derived correlates strongly provide a less resource-intensive method future longitudinal monitoring.

Language: Английский

Citations

3
Biomarkers for bladder cancer diagnosis, prognosis, monitoring and treatment DOI

Louise Stone

Nature Reviews Urology, Journal Year: 2022, Volume and Issue: 19(7), P. 383 - 383

Published: June 16, 2022

Language: Английский

Citations

5
Bladder cancer screening: The new selection and prediction model DOI Creative Commons
Vladan Radosavljević, Nataša Milić

Open Medicine, Journal Year: 2023, Volume and Issue: 18(1)

Published: Jan. 1, 2023

Abstract The objective of this study was to offer new approach for selection persons with asymptomatic bladder cancer (BC) and highly risky the BC occurrence. Also, it is a part screening protocol (study ongoing). Study populations were 100 newly diagnosed (diagnosis maximum 1-year old) males matched (by sex age ±5 years) controls (not oncology patients from same hospital). A hospital based, case–control done. Statistical analysis comprised four steps: t -test, univariate logistic regression, multivariate scoring. fifth step two changes, deleting one variable addition another variable. Six variables statistically significant: Caucasian men over 45 years age, tobacco smoking 40 pack-years, occupational and/or environmental exposure proved carcinogens 20 years, macrohematuria, difficulty urinating, in relatives up fourth degree kinships, they used an easy fast individuals high risk occurrence (optimal at population level). final results showed significant probability ( p < 0.001), area under ROC curve 0.913, negative predictive values 89.7% (95% CI 10.3–100%), specificity 78%. Positive value 80.5% 19.5–100%) sensitivity 91%. It possible recruit (primary prevention) by using model, as well (primordial prevention). This first second ongoing (urine analysis).

Language: Английский

Citations

2